MBX Biosciences (MBX) completed the last subject’s last visit in its Phase 1 single and multiple ascending dose trial of MBX 1416, the company’s long-acting glucagon-like peptide 1 receptor antagonist ...
Reports of fluoroquinolone-induced hypoglycemia are abundant, but reports of hyperglycemia induced by fluoroquinolones are also available. [15–19] The primary theory of fluoroquinolone ...